Inhibrx stockholders elect two Class I directors, ratify auditor at 2025 annual meeting

Inhibrx Biosciences, Inc.

Jon Faiz Kayyem, Ph.D. elected with 8,077,611 votes for, 31,060 withheld (3,384,613 broker non-votes).
Kristiina Vuori, M.D., Ph.D. elected with 6,494,317 votes for, 1,614,354 withheld (3,384,613 broker non-votes).
Ratification of BDO USA as auditor passed with 11,463,328 for, 2,918 against, 27,038 abstained.
Quorum of 11,493,284 shares (79% of eligible) was present at the May 28, 2025 virtual meeting.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.